- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer
Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the impact of the phase 3 PALOMA-2 trial (NCT01740427) in estrogen receptor (ER)–positive/HER2-negative advanced breast cancer.
The trial compared letrozole (Femara) in combination with palbociclib (Ibrance) vs letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative advanced breast cancer, Goetz explains.
Additional trials in the first-line setting, such as the phase 3 monarchE (NCT03155997) and MONALEESA-2 (NCT01958021) trials, tested different CDK4/6 inhibitors in combination with endocrine therapy, Goetz continues. The trials confirmed a benefit in progression-free survival with the addition of a CDK4/6 inhibitor to treatment, and as data have matured, investigators are beginning to gather overall survival data, Goetz concludes.
Related Content:
